Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
21 NC counties are under alert, including Northampton County.
Program
On WRAL at 6: WRAL Investigates why a school took nearly two years to report alleged abuse to law enforcement and parents.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sanofi - Aventis Groupe
< Previous
1
2
3
Next >
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
July 17, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
July 03, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
June 26, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
June 21, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
June 21, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
June 20, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
June 03, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
May 31, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 31, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
May 30, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
May 27, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
May 21, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 20, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 10, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
May 02, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Annual General Meeting of April 30, 2024
April 30, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
April 25, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
April 23, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
April 17, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
March 22, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
March 11, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
February 23, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
February 23, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
February 22, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
February 16, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
February 15, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
February 05, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
February 01, 2024
From
Sanofi - Aventis Groupe
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.